Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer
AF Henriksen, ANH Lundgren, MA Andersen, TA Gerds, AS Knop, TS Petersen, U Lassen, A Bjerrum · 2026
Read Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer by AF Henriksen, ANH Lundgren, MA Andersen, TA Gerds, AS Knop, TS Petersen, U Lassen, A Bjerrum (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579295.txt.
Description
A research team in eastern Denmark weighs in 2026 what changed when an immune drug joined early breast cancer care. The drug, pembrolizumab, became the standard add-on before surgery for a fast type of the disease. The team used health record data to match 210 patients treated just before and just after the switch.
After the switch, three in four patients got the drug, and a key chemo drug was skipped far less. Full tumor wipe-out at surgery rose from 49 to 68 percent. Grave side effects were a touch more common, and one in five drug-treated patients showed a grave self-attack flare, against none before. No deaths from side effects were found. Hand checks of 50 charts showed the record data were sound, with some gaps.
Catalog record
| CREATOR | AF Henriksen, ANH Lundgren, MA Andersen, TA Gerds, AS Knop, TS Petersen, U Lassen, A Bjerrum |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |